IMPACT OF MODERN ANTIHYPERTENSION MEDICATIONS ON THE CENTRAL PRESSURE AND ARTERIAL RIGIDITY
https://doi.org/10.15829/1728-8800-2015-5-13-18
Abstract
Aim. To study the impact of 16-week pharmacotherapy with а1,в- adrenoblocker carvedilol (С) on the parameters of pressure and vascular rigidity in arteries of different size in 1-2 grade arterial hypertension (AH) patients.
Material and methods. Totally 36 patients studied with AH of 1-2 grade at the age 49,9±9,4 y.o. We analyzed structural-functional parameters of the vessel wall, using methods of 24-hour blood pressure monitoring and assessment of the rigidity by Vasera-1000 equipment and current- related vasodilation (CRVD) in test with post occlusion reactive hyperemia by ultrasound device My Lab 90. All patients received С during 16 weeks treatment.
Results. At the background of pharmacotherapy, there was significant dynamic of aortic pressure by the data of 24-hour monitoring. There was a decrease of the mean 24-hour values of the central velocity of pulse wave (PWV) by 5,2% (p<0,01) with the absence of adverse influence on reflected pulse wave. By the data of volume-related sphygmography there was significant decrease of PWV in aorta by 13%, in mostly elastic arteries by 6% and muscular type — by 14% (p<0,05). While studying CRVD in post occlusion reactive hyperemia test the С therapy has also supported the improvement of endothelial function. Conclusion. 16-week С therapy, except BP normalization in various caliber arteries, improved structural-functional properties of the vessel wall.
About the Authors
L. I. Gusakovskaya
FSBEI "Penza State University". Penza, Russia
Russian Federation
Russian Federation
Yu. A. Tomashevskaya
FSBEI "Penza State University". Penza, Russia
Russian Federation
Russian Federation
A. A. Khromova
FSBEI "Penza State University". Penza, Russia
Russian Federation
Russian Federation
References
1. KobalavaZhD. New European guidelines for the management of arterial hypertension: long-awaited answers and new questions. Arterial hypertension 2014; 1(20): 19-26. Russian (КобалаваЖ.Д. Новые Европейские рекомендации по артериальной гипертонии: долгожданные ответы и новые вопросы. Артериальная гипертензия 2014; 1(20): 19-26).
2. Diagnostics and treatment of arterial hypertension. Russian guidelines (fourthreview). System hypertensia 2010; 3:5-26. Russian (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 5-26).
3. Boutouyrie Р, Achouba A, Trunet Р, Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipineatenolol combination: the EXPLOR study. Hypertension 2010; 55(6): 1314-22.
4. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of the European guidelines on hypertension management: a European Society of Hypertension Task Force document. Hypertension 2009; 27(11): 2121-58.
5. Belousov YB, Kukes VG, Lepahin VK, et al. Clinical pharmacology: national guidelines. M .: GEOTAR-Media, 2009; 976 p. Russian (Белоусов Ю.Б., Кукес В. Г., Лепахин В. К. и др. Клиническая фармакология: национальное руководство. М.: ГЭОТАР-Медиа, 2009; 976 с).
6. Nedogoda SV. Control of heart rate and elasticity of a vascular wall at treatment of arterial hypertension: how to reach the first one, without having worsened the second? Kardiologiia 2014; 3: 71-6. Russian (НедогодаС.В. Контроль частоты сердечных сокращений и эластичность сосудистой стенки при лечении артериальной гипертензии: как достичь первого, не ухудшив второго? Кардиология 2014; 3:71-6).
7. User Guide BPLab V. 3.2, Part 1, 2010; 149 p. Russian (Руководство пользователя ПО BPLab V. 3.2, Масть 1, 2010; 149 с).
8. Kotovskaya YV, Kravtsova OA, Pavlova EA. New in therapeutic strategy. Arterial hypertension 2014; 1(20):27-32. Russian (Котовская Ю. В., Кравцова О. A., Павлова Е.А. Новое в терапевтических стратегиях. Артериальная гипертензия 2014; 1(20): 27-32).
9. Mancia G, De Backer G, Dominiczak A, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Hypertension 2007; 25(9): 1105-87.
10. Doumas M, Gkaliagkousi E, Katsiki N. The Effect of Antihypertensive Drugs on Arterial Stiffness and Central Hemodynamics: Not All Fingers are Made the Same. The Open Hypertens J 2013; 5(Suppl.1:M5): 75-81.
11. De Luca N, Asmar RG, London GM. REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. Hypertension 2004; 22:1623-30.
12. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers a critical review of the evidence. JACC 2007; 50: 563-72.
13. Roman MJ, Kizer JR, Ali T, et aJ. Central blood pressure better predicts cardiovascular events than does peripheral blood pressure: The Strong Heart Study. Circulation 2005; 112 (suppl.11): 11-778.
14. Katakami N, Osonoi T, Takahara M, et al. Clinical utility of brachial-ankle pulse wave velocity in the prediction of cardiovascular events in diabetic patients. Cardiovascular
15. Diabetology 2014; 13:128.
16. Wang G, Zheng L, Li X, et al. Using brachial-ankle pulse wave velocity to screen for metabolic syndrome in community populations. Scientific Reports 2015; 5:9438.
17. Sun C. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. Integr Blood Press Control 2013; 6: 27-38.
18. Kartasheva ED, Linchak RM. Role of p-blockers in treatment and prevention of cardiovascular diseases: accent on carvedilol. Difficult patient 2010; 5(8): 21-7. Russian (Карташева Е.Д., ЛинчакР.М. Роль p-адреноблокаторов в лечении и профилактике сердечно-сосудистых заболеваний: акцент на карведилол. Трудный пациент 2010; 5(8): 21-7).
19. Lopez BL, Christopher ТА, YUe TL, et al. Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995; 51(3): 165-73.
20. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension 2004; 292(18): 2227-36.
21. Nebiyeridze DV. Clinical value of endotelial dysfunction in arterial hypertension. System hypertension 2005; 7(1):43-9. Russian (Небиеридзе Д.В. Клиническое значение дисфункции эндотелия при артериальной гипертонии. Системные гипертензии 2005; 7(1): 43-9).
22. Careri G, Neria R, Di Monaco A. Clinical correlates and prognostic value of flow mediated dilation in patients with non-ST segment elevation acute coronary syndromes. Am J Cardiol 2013; 111(1): 51-7.
23. Oleynikov VE, Matrosova IB. Vascular remodeling in arterial hypertension in patients older than 60 years. Features of therapy correction. Materials of the XVI Russian National Congress "Human and medicine". Moscow 2010; 2: 200-17. Russian (Олейников В.Э., Матросова И.Б. Сосудистое ремоделирование при артериальной гипертонии у лиц старше 60 лет. Возможности медикаментозной коррекции. Труды XVI Российского национального конгресса "Человек и лекарство". Москва 2010; 2: 200-17).
24. Jost S, Deckers J, Rafflenbeul W, et al. International nifedipine trial on antiatherosclerotic therapy (INTACT) — methodologic implications and results of a coronary angiographic follow-up study using computer-assisted film analysis. Int J Card Imaging 1990-1991; 6(2): 117-33.
Review
For citations:
Gusakovskaya L.I., Tomashevskaya Yu.A., Khromova A.A. IMPACT OF MODERN ANTIHYPERTENSION MEDICATIONS ON THE CENTRAL PRESSURE AND ARTERIAL RIGIDITY. Cardiovascular Therapy and Prevention. 2015;14(5):13-18. (In Russ.) https://doi.org/10.15829/1728-8800-2015-5-13-18
Views:
738
Email this article 
